Evidence map›Paper›PMID 39933715›Full record

ReviewAmerican journal of physiology. Renal physiology2025

Sphingolipid signaling in kidney diseases.

Ningjun Li, Guangbi Li

Abstract readReview
In one paragraph

Review in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ningjun LiDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0001-5371-3790
Guangbi LiDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0003-3836-3272

Funding

Renal sphingosine-1-phosphate receptor 1 in salt-sensitive hypertensionR01HL145163 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, NINGJUN · 2019 to 2022
$1.6M
Renal acid ceramidase-S1P pathway in salt-sensitive hypertensionR01DK140219 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI Ningjun Li · 2024 to 2026
$1.4M
Inhibition of diacylglycerol lipase α as a novel strategy to mitigate the nephrotoxicity of cisplatinR21CA289216 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Ningjun Li · 2025 to 2026
$409k
Inhibition of fatty acid amide hydrolase as a novel strategy to prevent nephrotoxicity of cisplatin.R21CA274012 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, NINGJUN · 2022 to 2023
$398k
HHS | NIH | National Cancer Institute (NCI) CA274012HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL145163NCI NIH HHS R21 CA274012NCI NIH HHS R21 CA289216NHLBI NIH HHS R01 HL145163NIDDK NIH HHS R01 DK140219
6 · The paper itself

Abstract

Sphingolipids are a family of bioactive lipids. The key components include ceramides, ceramide-1-phosphate, sphingosine, and sphingosine-1-phosphate. Sphingolipids were originally considered to be primarily structural elements of cell membranes but were later recognized as bioactive signaling molecules that play diverse roles in cellular behaviors such as cell differentiation, migration, proliferation, and death. Studies have demonstrated changes in key components of sphingolipids in the kidneys under different conditions and their important roles in the renal function and the pathogenesis of various kidney diseases. This review summarizes the most recent advances in the role of sphingolipid signaling in kidney diseases.

Indexed as

KidneyKidney DiseasesSignal TransductionSphingolipidsAnimalsCeramidesHumansLysophospholipidsSphingosineCeramidesLysophospholipidsSphingolipidsSphingosinesphingosine 1-phosphateblood pressureceramideinflammationsphingomyelinsphingosine-1-phosphate

Identifiers

PMID39933715
PMCPMC12177509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.